FDA Approves Briumvi (Ublituximab) for Relapsing Multiple Sclerosis
In case you haven’t heard the news by now, the FDA recently approved Briumvi (Ublituximab), by TG Therapeutics, for the treatment of relapsing-remitting Multiple Sclerosis.
The drug is now the 3rd CD20 anti-b-cell therapy on the market for Multiple Sclerosis. Up until now, Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) were the only B-cell targeting drugs available on the market.
This is great news, because B-cell therapies, such as the drugs named above, have all been proven highly effective as disease-modifying therapies for MS.
Given as a twice-yearly infusion, Briumvi is currently available for Relapsing-remitting MS (RRMS), Clinically-Isolated Syndrome (CIS), and Secondary-progressive MS (SPMS).
According to the MS News Today article below, “Briumvi was engineered to be more potent than other anti-CD20 therapies, allowing for lower doses and shorter infusion times.”
Read more about it here, on Multiple Sclerosis News Today
MS is a disease of the central nervous system that specifically targets the myelin sheath in the brain and spinal cord. Any time those with MS can get a new medication available to them on the market, it’s a huge victory in the fight against a disease that can take away almost every function in the human body.
If you’re one of us in the MS “club”, join us every 2nd and 4th Tuesdays of the month for our MS group meeting here